Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: ABY-029; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cervical Carcinoma, Endometrial Carcinoma
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8
Interventions: Carboplatin, Cemiplimab, Paclitaxel; Drug · Biological
Lead sponsor: Marcelo Bonomi; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer, Stomach Cancer
Interventions: Zanidatamab; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Orange, California • Houston, Texas

Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: iodine I 131 monoclonal antibody CC49-deltaCH2; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy; Biological · Drug · Genetic + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer, Throat Cancer, Tonsil Cancer
Interventions: NavDx, Adjuvant Radiation 30 Gray, Adjuvant Radiation 40 Gray; Diagnostic Test · Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Head and Neck Cancer
Interventions: Sterile Humidification Device; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer, Hypoxia, Magnetic Resonance Imaging, Cancer Neck
Interventions: [18F]MISO-PET/CT; Diagnostic Test
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Recurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions: eribulin mesylate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Carcinoma, Head and Neck Cancer, Lung Cancer
Interventions: Best Practice, Medical Device Usage and Evaluation, Respiratory Muscle Training, Survey Administration; Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer
Interventions: pralatrexate, docetaxel, fludeoxyglucose F 18, positron emission tomography; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Cancer, Taste Dysfunction, Radiation Therapy
Interventions: Intraoral Device; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
Interventions: Topotecan and pegylated doxorubicin; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Uterine Cervix Cancer
Interventions: Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy; Drug · Radiation
Lead sponsor: Denise Fabian; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
Interventions: arsenic trioxide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Anti-OX40 antibody administration, Surgical Resection; Drug · Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Head and Neck Cancer
Interventions: PET/MRI; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Oral Cancer, Squamous Cell Carcinoma
Interventions: Pressure and stretch sensitivity testing; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer of Head and Neck
Interventions: Metformin; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Head and Neck Cancer, Lymphedema, Fibrosis
Interventions: Low-level laser; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thyroid Cancer
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer
Interventions: PCA062; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Head and Neck Neoplasm, Malignant Head and Neck Neoplasm
Interventions: Computed Tomography Perfusion Imaging; Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

ABY-029 Head & Neck Phase 1 Trial

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx

Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients

Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

Intraoral Hypothermia Device for Preserving Taste During Radiation

Doxil Topotecan Doublet Cancer Study

Hypofractionated Radiochemotherapy

Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

Anti-OX40 Antibody in Head and Neck Cancer Patients

Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI

Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain

Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis

Low-Level Laser in Head and Neck Chronic Lymphedema

Nivolumab Plus Ipilimumab in Thyroid Cancer

PCA062 in pCAD-positive Tumors.

Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors